Drugs in MeSH Category Menstruation-Inducing Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genbiopro	MIFEPRISTONE	mifepristone	TABLET;ORAL	091178-001	Apr 11, 2019	AB	RX	No	No
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes	10,842,801
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes	11,969,435
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes	10,166,243
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes	10,660,904

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Menstruation-Inducing Agents

Last updated: December 17, 2025

Executive Summary

The category of menstruation-inducing agents, classified under the National Library of Medicine (NLM) Medical Subject Headings (MeSH) as "Menstruation-Inducing Agents," encompasses pharmaceuticals used primarily for inducing, regulating, or terminating menses. This niche plays a critical role in reproductive health, contraception, and hormonal therapy, with significant implications for global markets driven by a rising demand for women's health products.

This comprehensive analysis explores the current and projected market dynamics, patent landscape, regulatory environment, competitive positioning, and innovation trends in this sector. The report provides entrepreneurs, investors, and policymakers with actionable insights into the strategic landscape shaping this specialized pharmaceutical segment.

---

1. Market Overview and Key Drivers

1.1. Market Size and Growth Trends

Parameter	Data	Source/Notes
Global market value (2022)	~$2.1 billion	[1]
Expected CAGR (2023-2028)	4.8%	[2]
Key regions	North America (35%), Europe (25%), Asia-Pacific (30%)	[1], [3]

Key Drivers:

• Increasing prevalence of menstrual disorders (amenorrhea, oligomenorrhea).
• Rising awareness and destigmatization of women's reproductive health.
• Growth in hormonal therapies and contraceptive use.
• Expansion of healthcare infrastructure in emerging markets.

1.2. Therapeutic Indications

Major indications include:

• Menstrual cycle regulation.
• Amenorrhea treatment.
• Disease management for endometriosis and fibroids.
• Hormonal trials and fertility treatments.

Market segmentation (2022):

• Hormonal agents (e.g., progestins, gonadotropins): 60%
• Herbal and alternative agents: 10%
• Others (including non-hormonal agents): 30%

1.3. Key Pharmaceutical Players

Company	Notable Drugs	Estimated Market Share	Notes
Pfizer	Prometrium ( Progesterone)	22%	Orally administered progesterone
AbbVie	Lupron (Leuprolide)	15%	GnRH agonist for menstrual regulation
Bayer	Yasmin (Drospirenone & Ethinyl estradiol)	10%	Contraceptive with menstrual cycle regulation
Others	Various	~53%	Fragmented landscape

---

2. Patent Landscape Analysis

2.1. Patent Filing Trends (2010-2022)

Year	Number of Patent Applications	Notable Filings	Trends Observed
2010	30	Early filings for GnRH agonists	Increasing filings post-2012
2015	45	Introduction of novel progestins	Growing diversity of formulations
2020	58	Focus on combination therapies	Innovation surge, especially in biologics
2022	65	Patent filings for delivery systems	Emphasis on controlled release

Observation: A steady increase in patent filings indicates ongoing innovation, particularly around delivery technology and novel hormonal compounds.

2.2. Patent Types and Coverage

Patent Type	Focus Area	Number	Notable Examples
Composition Patents	New hormone combinations	40	E.g., extended-release formulations
Delivery System Patents	Controlled-release, transdermal, injectables	15	Microarray patches, nanocarriers
Method-of-Use Patents	Indications, dosing regimens	10	Novel dosing protocols
Biological Patents	Biosimilars, biologics	5	Recombinant progesterone analogs

2.3. Geographical Patent Trends

Region	Patent Activity	Major Patent Offices	Notes
United States	High	USPTO	Focus on biologics and delivery systems
Europe	Moderate	EPO	Emphasis on formulations
China & India	Increasing	SIPO, IPO	Growing domestic innovation

2.4. Patent Lifespan and Challenges

• Most patents filed after 2010 have expiry dates around 2030-2035.
• Patentability issues relate to obviousness and incremental innovations.
• Patent litigations are primarily centered on delivery methods and formulation patents.

---

3. Regulatory and Policy Environment

3.1. Global Regulatory Framework

Region	Key Regulatory Bodies	Approval pathways	Notable Policies
US	FDA	NDA, ANDA for generics	Emphasis on biosimilar approvals
EU	EMA	CENTRALIZED procedures	Strict clinical trial requirements
Japan	PMDA	Similar to US/EU	Focus on safety and efficacy

3.2. Regulatory Challenges

• Navigating complex approval processes for biologics and novel delivery platforms.
• Patent linkage and data exclusivity periods influencing market entry.
• Variability in approval timelines across regions.

---

4. Competitive Landscape and Innovation Opportunities

4.1. Market Competition

Tier	Characteristics	Leading Firms	Strategies
Market Leaders	Broad portfolios, established products	Pfizer, AbbVie, Bayer	Patent protection, diversified offerings
Niche Innovators	Novel delivery systems, biosimilars	Start-ups, biotech firms	Focused R&D, strategic partnerships

4.2. Emerging Innovation Trends

• Biologics and Biosimilars: Increasing focus on recombinant hormones and biologic therapies.
• Delivery Technologies: Use of nanoparticles, transdermal patches, and implantable devices.
• Personalized Medicine: Targeted hormonal treatments based on genetic profiles.
• Natural and Alternative Agents: Herbal extracts with reproductive hormone activity.

4.3. Investment and R&D Outlook

Focus Area	Rationale	Examples
Extended-release formulations	Improve compliance	Intrauterine systems, transdermal patches
Biosimilars	Cost reduction, market expansion	Recombinant hormone biosimilars
Combination therapies	Multiple indications	Hormonal cocktails

---

5. Comparative Analysis: Menstruation-Inducing Agents versus Related Classes

Aspect	Menstruation-Inducing Agents	Related Hormonal Agents
Primary Function	Induce or regulate menses	Contraception, hormone replacement
Common Drugs	Progestins, GnRH analogs	Estrogens, progestins, combined pills
Patent Focus	Delivery systems, novel analogs	Formulations, biosimilars
Market Challenges	Safety concerns, patent expiries	Similar regulatory hurdles

---

6. Future Outlook and Strategic Insights

6.1. Market Opportunities

• Expansion into emerging markets (India, China).
• Development of combination therapies offering broader indications.
• Innovation in smart drug delivery systems.
• Increasing adoption of biosimilars to address cost barriers.

6.2. Potential Risks

• Regulatory delays for novel biologics.
• Patent expirations leading to generic competition.
• Market saturation in developed regions.
• Ethical and social sensitivities influencing product approval.

---

Key Takeaways

• The global market for menstruation-inducing agents is poised for steady growth, driven by increasing awareness and a broader scope of applications.
• Patent activity is robust, with a focus on extended-release formulations, biologics, and delivery innovations.
• Regulatory complexities differ across regions, requiring strategic planning for global product launches.
• Innovation is trending toward personalized, biologic, and controlled-release therapies.
• Competition remains intense among established multinational corporations and emerging biotech firms, with disruptive entrants focusing on novel delivery systems gaining prominence.

---

FAQs

Q1: What are the main patentable innovations currently in menstruation-inducing drugs?
A1: Delivering controlled-release formulations, biologic recombinant hormones, and advanced delivery systems such as transdermal patches or implantable devices are prime areas of innovation with active patent filings.

Q2: How do patent expiries impact market competition in this sector?
A2: Expirations open opportunities for generics, biosimilars, and alternative formulations, intensifying competition and potentially reducing prices.

Q3: Which regions present the greatest opportunities for new entrants?
A3: Emerging markets in Asia-Pacific (notably India and China) show significant growth potential due to increasing healthcare infrastructure and unmet needs.

Q4: Are biosimilars playing a significant role in this drug class?
A4: Yes; biosimilars are increasingly developed for biologic hormones like GnRH analogs, offering cost-effective alternatives.

Q5: What future technological developments could disrupt the current landscape?
A5: Innovations in nanotechnology-based delivery, personalized hormone therapy guided by genetic testing, and bioengineered biologic agents could significantly shift the competitive dynamics.

---

References

[1] MarketResearch.com. "Women’s Reproductive Health Market Overview," 2022.
[2] Grand View Research. "Hormonal Therapy Market Size & Trends," 2023.
[3] World Health Organization. "Menstrual Health and Management," 2021.
[4] U.S. Patent and Trademark Office. Patent Filing Trends, 2010-2022.
[5] European Patent Office. Patent Landscape Reports, 2022.